PreComb constantly seeks to broaden its clinical network in order to enhance patient accessibility and promote scientific collaboration. If you are interested in joining our efforts to advance personalized medicine capabilities, please get in touch to explore new partnership opportunities with us.
For Pharma and Biotech Companies
PreComb, in conjunction with its clinical partners, provides a distinctive opportunity to test investigational drugs and drug combinations on tumor twins derived from primary human tumor tissue, enabling the evaluation of clinical effectiveness.
For Clinical Investigators
PreComb is dedicated to extending its clinical network to improve patient reach and foster scientific collaboration. If you are interested in contributing to the development of personalized medicine capabilities, we encourage you to contact us.
Our key clinical collaborations include:
University Hospital Zürich, Switzerland
PreComb collaborates with Prof. Dr. Chantal Pauli and Prof. Dr. med. Holger Moch of the Institute of Pathology and Molecular Pathology at the University Hospital Zürich (USZ) to develop novel prognostic models for pancreatic cancer and sarcoma patients.
Hopp Children's Cancer Center (KiTZ) of DKFZ, University Heidelberg and University Hospital Heidelberg, Germany
PreComb collaborates with Prof. Dr. Olaf Witt and PD Dr. Ina Oehme to clinically validate the PreComb’s fully automated drug profiling solution (3DTwin™ technology) in pediatric patients. The “Hopp Children’s Cancer Center Heidelberg” (KiTZ) is a joint institution of the German Cancer Research Center (DKFZ), the Heidelberg University and the Heidelberg University Hospital.
Medical University Innsbruck, Austria
PreComb collaborates with Dr. med. Arno Amann and Prof. Dr. med. Dominik Wolf of the Department of Internal Medicine V at the Medical University Innsbruck to explore the potential of patient-derived microtumors to predict the response of immune-oncological drugs.